Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
Funding Amount
Not stated
Deadline
Forecast — dates not yet posted
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Small businesses
- This opportunity is available to first-time Principal Investigators, and key personnel must include a mentor with measurable effort committed to the project.
- Individuals are eligible to serve as the PD/PI if they have never been an independent PD/PI on an NIH or CDC research, or corresponding non-NIH peer-reviewed research grant, and are a U.S.
Geography
- Citizen or Lawful Permanent Resident.
Other requirements
- Only United States small business concerns (SBCs), as defined by the Small Business Administration (SBA)(sbir.gov/apply) are eligible to submit applications for this opportunity.
Overview
The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC), including the participating Institutes, Centers and Offices, intend to publish a Notice of Funding Opportunity (NOFO) to invite eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) Phase I, and Fast-Track (NIH only) grant applications for the Small Business Transition Grant. Through this NOFO, NIH and CDC will support early-career scientists as they transition into entrepreneurship. In addition to funding research and development efforts at the SBC, a major component of this NOFO is entrepreneurial training, mentoring, and career development of the PD/PI. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop responsive projects, including identification of complementary industry mentors and career development resources. This NOFO will utilize the R43/R44 activity code. United States small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH and CDC awarding components identified in this NOFO are encouraged to begin to consider applying for this new NOFO. This opportunity is available to first-time Principal Investigators, and key personnel must include a mentor with measurable effort committed to the project.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: PAR-27-039
- Instrument: grant
Eligibility
Only United States small business concerns (SBCs), as defined by the Small Business Administration (SBA)(sbir.gov/apply) are eligible to submit applications for this opportunity. Individuals are eligible to serve as the PD/PI if they have never been an independent PD/PI on an NIH or CDC research, or corresponding non-NIH peer-reviewed research grant, and are a U.S. Citizen or Lawful Permanent Resident.
Focus Areas & Funding Uses
Fields of Work
- Small businesses
- Startups
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
National Institutes of Health
Amount
Varies
Deadline
October 6, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $1M
Deadline
October 9, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 9, 2026
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$650,000 total
Deadline
October 9, 2026
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Ready to apply for Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional). Now let's win it.